Unfortunately, this clinical trial was designed before the introduction of Cyclin-Dependent Kinase 4/6 inhibitors, which have proven their significant advantage in terms of PFS and partially OS, thus delaying the need to introduce CT in luminal breast cancer [2,16,17]. This evidence concerns the gene CDK4 and breast cancer.